Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-Reported Outcomes and MRI Assessment
Aesthetic Surgery Journal · 20.05.2026
DOI: 10.1093/asj/sjag092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 20.05.2026. Verfasst von Z Paul Lorenc und 10 weiteren Autor:innen. Beteiligte Einrichtung: Private practice in New York, NY. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Caliway Biopharmaceuticals.
Abstract (Originalsprache)
Background
CBL-514, a small-molecule injectable lipolysis agent that induces adipocyte apoptosis, demonstrated clinically meaningful reductions in abdominal subcutaneous fat by ultrasound in previous Phase 2 studies, with no observed necrosis or nerve injury.
Objectives
To evaluate the efficacy and safety of CBL-514 for abdominal subcutaneous fat reduction using clinician-reported scale, patient-reported scale, and MRI assessments.
Methods
In this randomized, single-blind, placebo-controlled Phase 2b trial (NCT05736107), 108 adults with moderate (Grade 3) to severe (Grade 4) abdominal subcutaneous fat were randomized 1:1 to receive up to 4 CBL-514 (2 mg/cm2; ≤600 mg/treatment) or placebo treatments at 3-week intervals. Primary efficacy was the proportion of participants with ≥1-grade improvement on the Clinician-Reported Abdominal Fat Rating Scale (CR-AFRS) at 12-week follow-up. Secondary endpoints included patient-reported AFRS, MRI-assessed changes in abdominal fat volume and thickness, and safety.
Results
In the full analysis set, 76.7% (23/30) of CBL-514-treated participants achieved ≥1-grade CR-AFRS improvement vs 18.9% (7/37) with placebo (P < .0001). Patient-reported AFRS results were similar, with 76.7% (23/30) of CBL-514 participants achieving ≥1-grade improvement vs 19.4% (7/36) in placebo (P < .0001). MRI demonstrated least squares (LS) mean abdominal fat volume reduction compared with baseline of −152.9 mL ± 17.75, with LS mean percent changes of −20.3%, both significantly greater than placebo (P < .0001). Most responders demonstrated improvement on the CR-AFRS after 1 to 2 treatments. CBL-514 was well tolerated, with mainly mild, transient injection site reactions.
Conclusions
CBL-514 significantly reduced abdominal fat by patient- and clinician-reported outcomes and MRI, with a favorable safety profile supporting its potential as a minimally invasive option. Level of Evidence: 2 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Autor:innen und Institutionen
- Private practice in New York, NY.
- Department of Plastic Surgery, Lenox Hill Hospital, New York, NY.
- Private practice in Nashville, TN.
- Private practice in Omaha, NE.
- Private practice in Austin, TX.
- Private practice in Encinitas, CA.
Förderung
- Caliway Biopharmaceuticals
Zitieren
APA
Lorenc, Z. P., Gold, M., Schlessinger, J., Lain, E. T., Smith, S., Downie, J., Cox, S. E., Ling, Y. F., Sheu, A. Y., Lu, C. Y., & Chou, Y. C. (2026). Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-Reported Outcomes and MRI Assessment. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjag092
Vancouver
Lorenc ZP, Gold M, Schlessinger J, Lain ET, Smith S, Downie J, et al. Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-Reported Outcomes and MRI Assessment. Aesthetic Surgery Journal. 2026. doi:10.1093/asj/sjag092
BibTeX
@article{Lorenc2026,
author = {Lorenc, Z Paul and Gold, Michael and Schlessinger, Joel and Lain, Edward Ted and Smith, Stacy and Downie, Jeanine and Cox, Sue Ellen and Ling, Yu-Fang and Sheu, An-Yi and Lu, Chih-Yun and Chou, Yin-Chia},
title = {Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-Reported Outcomes and MRI Assessment},
journal = {Aesthetic Surgery Journal},
year = {2026},
doi = {10.1093/asj/sjag092}
}
EUVIMED